A Clinical Update on SARS-CoV-2: Pathology and Development of Potential Inhibitors
-
Published:2023-01-04
Issue:1
Volume:45
Page:400-433
-
ISSN:1467-3045
-
Container-title:Current Issues in Molecular Biology
-
language:en
-
Short-container-title:CIMB
Author:
Singh Desh DeepakORCID, Han IhnORCID, Choi Eun-Ha, Yadav Dharmendra Kumar
Abstract
SARS-CoV-2 (severe acute respiratory syndrome) is highly infectious and causes severe acute respiratory distress syndrome (SARD), immune suppression, and multi-organ failure. For SARS-CoV-2, only supportive treatment options are available, such as oxygen supportive therapy, ventilator support, antibiotics for secondary infections, mineral and fluid treatment, and a significant subset of repurposed effective drugs. Viral targeted inhibitors are the most suitable molecules, such as ACE2 (angiotensin-converting enzyme-2) and RBD (receptor-binding domain) protein-based inhibitors, inhibitors of host proteases, inhibitors of viral proteases 3CLpro (3C-like proteinase) and PLpro (papain-like protease), inhibitors of replicative enzymes, inhibitors of viral attachment of SARS-CoV-2 to the ACE2 receptor and TMPRSS2 (transmembrane serine proteinase 2), inhibitors of HR1 (Heptad Repeat 1)–HR2 (Heptad Repeat 2) interaction at the S2 protein of the coronavirus, etc. Targeting the cathepsin L proteinase, peptide analogues, monoclonal antibodies, and protein chimaeras as RBD inhibitors interferes with the spike protein’s ability to fuse to the membrane. Targeting the cathepsin L proteinase, peptide analogues, monoclonal antibodies, and protein chimaeras as RBD inhibitors interferes with the spike protein’s ability to fuse to the membrane. Even with the tremendous progress made, creating effective drugs remains difficult. To develop COVID-19 treatment alternatives, clinical studies are examining a variety of therapy categories, including antibodies, antivirals, cell-based therapy, repurposed diagnostic medicines, and more. In this article, we discuss recent clinical updates on SARS-CoV-2 infection, clinical characteristics, diagnosis, immunopathology, the new emergence of variant, SARS-CoV-2, various approaches to drug development and treatment options. The development of therapies has been complicated by the global occurrence of many SARS-CoV-2 mutations. Discussion of this manuscript will provide new insight into drug pathophysiology and drug development.
Funder
National Research Foundation of Korea
Subject
Microbiology (medical),Molecular Biology,General Medicine,Microbiology
Reference135 articles.
1. Abouelela, M.E., Assaf, H.K., Abdelhamid, R.A., Elkhyat, E.S., Sayed, A.M., Oszako, T., Belbahri, L., El Zowalaty, A.E., and Abdelkader, M.S.A. (2021). Identification of Potential SARS-CoV-2 Main Protease and Spike Protein Inhibitors from the Genus Aloe: An In Silico Study for Drug Development. Molecules, 26. 2. Overhoff, B., Falls, Z., Mangione, W., and Samudrala, R. (2021). A Deep-Learning Proteomic-Scale Approach for Drug Design. Pharmaceuticals, 14. 3. Meng, J., Li, R., Zhang, Z., Wang, J., Huang, Q., Nie, D., Fan, K., Guo, W., Zhao, Z., and Han, Z. (2022). A Review of Potential Therapeutic Strategies for COVID-19. Viruses, 14. 4. Starshinova, A., Malkova, A., Zinchenko, U., Kudlay, D., Glushkova, A., Dovgalyk, I., Yablonskiy, P., and Shoenfeld, Y. (2021). Efficacy of Different Types of Therapy for COVID-19: A Comprehensive Review. Life, 11. 5. Gherghescu, I., and Delgado-Charro, M.B. (2021). The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA. Pharmaceutics, 13.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|